The firm is a therapeutics-focused venture builder and investment firm that partners with founders to discover, develop, and advance innovative medicines. The firm supports company creation through direct investments, focused spinouts, and de novo company formation. Combining venture investing with extensive drug discovery and development capabilities, the firm provides hands-on scientific, operational, and strategic support through a large multidisciplinary team of drug discovery experts, development professionals, and company builders. The firm invests through dedicated early- and clinical-stage funds, supporting programs from concept through key preclinical and clinical value-inflection milestones.
The firm invests exclusively in therapeutics and is agnostic across modalities and disease areas. The firm supports both single-asset and platform companies and is willing to invest across a broad spectrum of maturity, ranging from well-defined scientific concepts to companies with substantial preclinical proof-of-concept or early clinical data. The firm focuses on advancing programs through major development milestones, including preclinical validation, development candidate selection, and clinical demonstration of therapeutic activity.
From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. Instead, the firm works as a highly collaborative partner, providing scientific, operational, and strategic guidance to help founders optimize development plans, generate high-quality data, and maximize long-term value creation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment